Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Conditions
Interventions
Ibrutinib
Placebo
+5 more
Locations
201
United States
Tucson, Arizona, United States
Greenbrae, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Salinas, California, United States
Stanford, California, United States
Start Date
September 3, 2013
Primary Completion Date
February 26, 2018
Completion Date
April 5, 2019
Last Updated
February 4, 2025
NCT07249528
NCT04570423
NCT00131014
NCT03050268
NCT07545603
NCT07137494
Lead Sponsor
Janssen Research & Development, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions